{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:23:23Z","timestamp":1784568203804,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10458-7","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:02:16Z","timestamp":1744862536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions"],"prefix":"10.1007","volume":"52","author":[{"given":"Toka","family":"Elemary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E. A.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Zaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"1","key":"10458_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40779-022-00410-2","volume":"9","author":"M Razavi","year":"2022","unstructured":"Razavi M, Wei YY, Rao XQ, Zhong JX (2022) DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Mil Med Res 9(1):1\u201315. https:\/\/doi.org\/10.1186\/s40779-022-00410-2","journal-title":"Mil Med Res"},{"key":"10458_CR2","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00210-022-02279-3","volume":"395","author":"EM Zakaria","year":"2022","unstructured":"Zakaria EM, Tawfeek WM, Hassanin MH et al (2022) Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 395:1357\u20131372. https:\/\/doi.org\/10.1007\/s00210-022-02279-3","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"Supplement_1","key":"10458_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024. Diabetes Care 47(Supplement_1):158\u2013178. https:\/\/doi.org\/10.2337\/dc24-S009","journal-title":"Diabetes Care"},{"key":"10458_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00376","volume":"10","author":"B Ahr\u00e9n","year":"2019","unstructured":"Ahr\u00e9n B (2019) DPP-4 inhibition and the path to clinical proof. Front Endocrinol 10:1\u201318. https:\/\/doi.org\/10.3389\/fendo.2019.00376","journal-title":"Front Endocrinol"},{"key":"10458_CR5","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2147\/DMSO.S450994","volume":"17","author":"R Chen","year":"2024","unstructured":"Chen R, Li J, Chen D, Wen W, Zhang S, Li J, Ruan Y, Zhang Z, Sun J, Chen H (2024) Efficacy and safety of DPP-4 inhibitors and metformin combinations in type 2 diabetes: a systematic literature review and network meta-analysis. Diabetes, Metabolic Syndrome and Obes 17:2471\u20132493. https:\/\/doi.org\/10.2147\/DMSO.S450994","journal-title":"Diabetes, Metabolic Syndrome and Obes"},{"issue":"1","key":"10458_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/agm2.12294","volume":"7","author":"L Guo","year":"2024","unstructured":"Guo L, Xiao X (2024) Guideline for the management of diabetes mellitus in the elderly in China (2024 Edition). Aging Med 7(1):5\u201351. https:\/\/doi.org\/10.1002\/agm2.12294","journal-title":"Aging Med"},{"issue":"5","key":"10458_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, Isaacs SD, Izuora KE, Low Wang CC, Twining CL, Umpierrez GE, Valencia WM (2023) American association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm \u2013 2023 update. Endocr Pract 29(5):305\u2013340. https:\/\/doi.org\/10.1016\/j.eprac.2023.02.001","journal-title":"Endocr Pract"},{"key":"10458_CR8","doi-asserted-by":"publisher","first-page":"154295","DOI":"10.1016\/j.metabol.2020.154295","volume":"109","author":"AP Stoian","year":"2020","unstructured":"Stoian AP, Sachinidis A, Stoica RA, Nikolic D, Patti AM, Rizvi AA (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism: Clin and Exp 109:154295. https:\/\/doi.org\/10.1016\/j.metabol.2020.154295","journal-title":"Metabolism: Clin and Exp"},{"issue":"12","key":"10458_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/1440-1681.13561","volume":"48","author":"SH Elhini","year":"2021","unstructured":"Elhini SH, Hussien AK, Omran AAE, Elsayed AA, Saeed H (2021) Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects. Clin and Exp Pharmacology and Physiol 48(12):1589\u20131602. https:\/\/doi.org\/10.1111\/1440-1681.13561","journal-title":"Clin and Exp Pharmacology and Physiol"},{"key":"10458_CR10","doi-asserted-by":"publisher","DOI":"10.35248\/2155-6156.21.12.890","author":"AG Moussa","year":"2021","unstructured":"Moussa AG, Gamal AA, Ibrahim OM et al (2021) Effect of vildagliptin versus vildagliptin plus metformin on nonalcoholic fatty liver disease patients with type 2 diabetes mellitus. J Diabetes Metab. https:\/\/doi.org\/10.35248\/2155-6156.21.12.890","journal-title":"J Diabetes Metab"},{"key":"10458_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2023.1130625","volume":"10","author":"K Saini","year":"2023","unstructured":"Saini K, Sharma S, Khan Y (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Front Mol Biosci 10:1\u201319. https:\/\/doi.org\/10.3389\/fmolb.2023.1130625","journal-title":"Front Mol Biosci"},{"issue":"5","key":"10458_CR12","first-page":"223","volume":"12","author":"P Rai","year":"2019","unstructured":"Rai P, Dwibedi N, Rowneki M, Helmer DA, Sambamoorthi U (2019) Dipeptidyl peptidase-4 inhibitors and joint pain: a retrospective cohort study of older veterans with type 2 diabetes mellitus. Am Health & Drug Benefits 12(5):223\u2013231","journal-title":"Am Health & Drug Benefits"},{"issue":"3","key":"10458_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.56397\/IST.2024.05.04","volume":"3","author":"D Mohajan","year":"2023","unstructured":"Mohajan D, Mohajan HK (2023) Dipeptidyl peptidase-4 (DPP-4) inhibitors: new oral medications for the treatment of type 2 diabetes. Innovation in Sci and Technol 3(3):31\u201335. https:\/\/doi.org\/10.56397\/IST.2024.05.04","journal-title":"Innovation in Sci and Technol"},{"issue":"4","key":"10458_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/jcm9040912","volume":"9","author":"AM Patti","year":"2020","unstructured":"Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F (2020) Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J of Clinical Med 9(4):912. https:\/\/doi.org\/10.3390\/jcm9040912","journal-title":"J of Clinical Med"},{"key":"10458_CR15","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.2147\/JIR.S380285","volume":"15","author":"SY Chen","year":"2022","unstructured":"Chen SY, Kong XQ, Zhang KF, Luo S, Wang F, Zhang JJ (2022) DPP4 as a potential candidate in cardiovascular disease. J Inflamm Res 15:5457\u20135469. https:\/\/doi.org\/10.2147\/JIR.S380285","journal-title":"J Inflamm Res"},{"issue":"4674","key":"10458_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm13164674","volume":"13","author":"R Le","year":"2024","unstructured":"Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA, Psaltis PJ (2024) Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs. J Clin Med 13(4674):1\u201331. https:\/\/doi.org\/10.3390\/jcm13164674","journal-title":"J Clin Med"},{"issue":"7","key":"10458_CR17","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","volume":"137","author":"BP Bullock","year":"1996","unstructured":"Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137(7):2968\u20132978. https:\/\/doi.org\/10.1210\/endo.137.7.8770921","journal-title":"Endocrinology"},{"issue":"1","key":"10458_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S, Pawelke F, Kus K, Kr\u00f6ller-Sch\u00f6n S, Oelze M, Chlopicki S, Schuppan D, Wenzel P, Ruf W, Drucker DJ, M\u00fcnzel T, Daiber A, Steven S (2020) Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol 40(1):145\u2013158. https:\/\/doi.org\/10.1161\/atv.0000615456.97862.30","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10458_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.diabres.2019.02.006","volume":"149","author":"AM Patti","year":"2019","unstructured":"Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, Citarrella R, Corrado E, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M (2019) Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: an 8-month prospective study. Diabetes Res Clin Pract 149:163\u2013169. https:\/\/doi.org\/10.1016\/j.diabres.2019.02.006","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10458_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/cdt-23-349","volume":"14","author":"A Her","year":"2024","unstructured":"Her A, Choi BG, Rha S, Kim YH, Jeong MH (2024) Dipeptidyl peptidase-4 inhibitors versus sulfonylureas on the top of metformin in patients with diabetes and acute myocardial infarction. Cardiovasc Diagnosis and Ther 14(1):38\u201350. https:\/\/doi.org\/10.21037\/cdt-23-349","journal-title":"Cardiovasc Diagnosis and Ther"},{"key":"10458_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01355-5","author":"KV Patel","year":"2020","unstructured":"Patel KV, Sarraju A, Neeland IJ, McGuire DK (2020) Cardiovascular effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists: a review for the general cardiologist. Current Cardiol Rep. https:\/\/doi.org\/10.1007\/s11886-020-01355-5","journal-title":"Current Cardiol Rep"},{"key":"10458_CR22","doi-asserted-by":"publisher","unstructured":"Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., Raz, I., & SAVOR-TIMI 53 Steering Committee and Investigators (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. The New England Journal of Medicine, 369(14): 1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","DOI":"10.1056\/NEJMoa1307684"},{"issue":"8","key":"10458_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/dom.12925","volume":"19","author":"SA de Boer","year":"2017","unstructured":"de Boer SA, Heerspink HJL, Ju\u00e1rez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, Slart RHJA, Lefrandt JD, Mulder DJ (2017) Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab 19(8):1147\u20131154. https:\/\/doi.org\/10.1111\/dom.12925","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10458_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-016-0493-3","volume":"16","author":"T Jax","year":"2017","unstructured":"Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, Eynatten M, Marx N (2017) A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol 16(1):1\u201316. https:\/\/doi.org\/10.1186\/s12933-016-0493-3","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10458_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, Von Eynatten M, McGuire DK (2018) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA - J Am Med Assoc 321(1):69\u201379. https:\/\/doi.org\/10.1001\/jama.2018.18269","journal-title":"JAMA - J Am Med Assoc"},{"issue":"1","key":"10458_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-023-02001-z","volume":"23","author":"CS Kuo","year":"2024","unstructured":"Kuo CS, Kuo NR, Yeh YK, Lee YJ, Chuang LM, Chen HF, Chen CC, Lee CC, Hsu CC, Li HY, Ou HY, Hwu CM (2024) Residual risk of cardiovascular complications in statin-using patients with type 2 diabetes: the Taiwan diabetes registry study. Lipids Health Dis 23(1):1\u201311. https:\/\/doi.org\/10.1186\/s12944-023-02001-z","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10458_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dbi20-0049","volume":"71","author":"JR Ussher","year":"2022","unstructured":"Ussher JR, Greenwell AA, Nguyen MA, Mulvihill EE (2022) Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials. Diabetes 71(2):173\u2013183. https:\/\/doi.org\/10.2337\/dbi20-0049","journal-title":"Diabetes"},{"issue":"3","key":"10458_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4103\/jod.jod_80_24","volume":"15","author":"KT Hau","year":"2024","unstructured":"Hau KT, Mafauzy M, Bin LX (2024) Systematic review of cardiovascular outcomes wth sulfonylureas, GLP-1 RA, and DPP-4 inhibitors in type 2 diabetes mellitus. J of Diabetology 15(3):266\u2013272. https:\/\/doi.org\/10.4103\/jod.jod_80_24","journal-title":"J of Diabetology"},{"key":"10458_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1184572","volume":"14","author":"LY He","year":"2023","unstructured":"He LY, Li Y, Niu SQ, Bai J, Liu SJ, Guo JL (2023) Polysaccharides from natural resource: ameliorate type 2 diabetes mellitus via regulation of oxidative stress network. Front Pharmacol 14:1\u201320. https:\/\/doi.org\/10.3389\/fphar.2023.1184572","journal-title":"Front Pharmacol"},{"issue":"10","key":"10458_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","volume":"122","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ (2018) Cardiovascular effects of new oral glucose-lowering agents DPP-4 and SGLT-2 inhibitors. Circ Res 122(10):1439\u20131459. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311588","journal-title":"Circ Res"},{"issue":"1","key":"10458_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/13813455.2021.1975758","volume":"130","author":"MM Allam","year":"2024","unstructured":"Allam MM, Ibrahim RM, El Gazzar WB, Said MA (2024) Dipeptedyl peptidase-4 (DPP-4) inhibitor downregulates HMGB1\/TLR4\/NF-\u03baB signaling pathway in a diabetic rat model of non-alcoholic fatty liver disease. Arch Physiol Biochem 130(1):87\u201395. https:\/\/doi.org\/10.1080\/13813455.2021.1975758","journal-title":"Arch Physiol Biochem"},{"key":"10458_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/11795514211051698","author":"SM Kang","year":"2021","unstructured":"Kang SM, Park JH (2021) Pleiotropic benefits of DPP-4 inhibitors beyond glycemic control. Clin Med Insights Endocrinol and Diabetes. https:\/\/doi.org\/10.1177\/11795514211051698","journal-title":"Clin Med Insights Endocrinol and Diabetes"},{"issue":"6","key":"10458_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/abbs\/gmaa038","volume":"52","author":"S Fan","year":"2020","unstructured":"Fan S, Xiong Q, Zhang X, Zhang L, Shi Y (2020) Glucagon-like peptide 1 reverses myocardial hypertrophy through cAMP\/PKA\/RhoA\/ROCK2 signaling. Acta Biochim Biophys Sin 52(6):612\u2013619. https:\/\/doi.org\/10.1093\/abbs\/gmaa038","journal-title":"Acta Biochim Biophys Sin"},{"issue":"6","key":"10458_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/ph15060720","volume":"15","author":"A Ismaeil","year":"2022","unstructured":"Ismaeil A, Babiker F, Al-Sabah S (2022) Discrepancy between the actions of glucagon-like peptide-1 receptor ligands in the protection of the heart against ischemia reperfusion injury. Pharmaceuticals 15(6):720. https:\/\/doi.org\/10.3390\/ph15060720","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10458_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13300-022-01217-z","volume":"13","author":"D Nikolic","year":"2022","unstructured":"Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Mag\u00e1n-Fern\u00e1ndez A, Citarrella R, Papanas N, Janez A, Stoian AP, Rizvi AA, Rizzo M (2022) Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study. Diabetes Ther 13(3):453\u2013464. https:\/\/doi.org\/10.1007\/s13300-022-01217-z","journal-title":"Diabetes Ther"},{"issue":"9","key":"10458_CR36","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1016\/j.bbadis.2018.05.012","volume":"1864","author":"M Rizzo","year":"2018","unstructured":"Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, Rizvi AA, Cosentino F (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochimica et Biophysica Acta - Mol Basis of Dis 1864(9):2814\u20132821. https:\/\/doi.org\/10.1016\/j.bbadis.2018.05.012","journal-title":"Biochimica et Biophysica Acta - Mol Basis of Dis"},{"key":"10458_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2021.738848","volume":"12","author":"S Puglisi","year":"2021","unstructured":"Puglisi S, Rossini A, Poli R, Dughera F, Pia A, Terzolo M, Reimondo G (2021) Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol 12:1\u201310. https:\/\/doi.org\/10.3389\/fendo.2021.738848","journal-title":"Front Endocrinol"},{"issue":"2","key":"10458_CR38","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","volume":"41","author":"JH Yu","year":"2022","unstructured":"Yu JH, Park SY, Lee DY, Kim NH, Seo JA (2022) GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Res and Clin Pract 41(2):136\u2013149. https:\/\/doi.org\/10.23876\/j.krcp.22.001","journal-title":"Kidney Res and Clin Pract"},{"issue":"1","key":"10458_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00424-021-02596-1","volume":"474","author":"NL Rukavina Mikusic","year":"2022","unstructured":"Rukavina Mikusic NL, Kouyoumdzian NM, Puy\u00f3 AM, Fern\u00e1ndez BE, Choi MR (2022) Role of natriuretic peptides in the cardiovascular-adipose communication: a tale of two organs. Pflugers Arch 474(1):5\u201319. https:\/\/doi.org\/10.1007\/s00424-021-02596-1","journal-title":"Pflugers Arch"},{"issue":"2","key":"10458_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1074248420952243","volume":"26","author":"AV Krylatov","year":"2021","unstructured":"Krylatov AV, Tsibulnikov SY, Mukhomedzyanov AV, Boshchenko AA, Goldberg VE, Jaggi AS, Erben RG, Maslov LN (2021) The role of natriuretic peptides in the regulation of cardiac tolerance to ischemia\/reperfusion and postinfarction heart remodeling. J Cardiovasc Pharmacol Ther 26(2):131\u2013148. https:\/\/doi.org\/10.1177\/1074248420952243","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"2","key":"10458_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10741-020-10005-5","volume":"26","author":"M Rankovic","year":"2021","unstructured":"Rankovic M, Jeremic N, Srejovic I, Radonjic K, Stojanovic A, Glisic M, Bolevich S, Bolevich S, Jakovljevic V (2021) Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection. Heart Fail Rev 26(2):437\u2013450. https:\/\/doi.org\/10.1007\/s10741-020-10005-5","journal-title":"Heart Fail Rev"},{"key":"10458_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.trsl.2018.10.006","volume":"205","author":"AJ Whittam","year":"2019","unstructured":"Whittam AJ, Maan ZN, Duscher D, Barrera JA, Hu MS, Fischer LH, Khong S, Kwon SH, Wong VW, Walmsley GG, Giacco F, Januszyk M, Brownlee M, Longaker MT, Gurtner GC (2019) Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds. Translational Res: The J of Lab and Clin Med 205:51\u201363. https:\/\/doi.org\/10.1016\/j.trsl.2018.10.006","journal-title":"Translational Res: The J of Lab and Clin Med"},{"issue":"1","key":"10458_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12933-018-0702-3","volume":"17","author":"F Chiazza","year":"2018","unstructured":"Chiazza F, Tammen H, Pintana H et al (2018) The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1\u03b1\/CXCR4 pathway. Cardiovasc Diabetol 17(1):60. https:\/\/doi.org\/10.1186\/s12933-018-0702-3","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10458_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.arcmed.2019.07.004","volume":"50","author":"M Li","year":"2019","unstructured":"Li M, Wang Z, Xia H, Yu L, Hu Z (2019) Vildagliptin and G-CSF improved angiogenesis and survival after acute myocardial infarction. Arch Med Res 50(3):133\u2013141. https:\/\/doi.org\/10.1016\/j.arcmed.2019.07.004","journal-title":"Arch Med Res"},{"issue":"10","key":"10458_CR45","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/cells10102659","volume":"10","author":"A Widiapradja","year":"2021","unstructured":"Widiapradja A, Kasparian AO, McCaffrey SL, Kolb LL, Imig JD, Lacey JL, Melendez GC, Levick SP (2021) Replacement of lost substance p reduces fibrosis in the diabetic heart by preventing adverse fibroblast and macrophage phenotype changes. Cells 10(10):2659. https:\/\/doi.org\/10.3390\/cells10102659","journal-title":"Cells"},{"issue":"9","key":"10458_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.14715\/cmb\/2023.69.9.15","volume":"69","author":"M Abdullah Ali","year":"2023","unstructured":"Abdullah Ali M, Naji Alhassani A, Kareem Hamad B (2023) Impacts of trelagliptin and remogliflozin alone and in combination with alpha lipoic acid on cardiac function in streptozotocin-induced diabetes mellitus in rats: effects of trelagliptin, remogliflozin, and ALA on cardiac function in DCM. Cell and Mol Biol 69(9):106\u2013112. https:\/\/doi.org\/10.14715\/cmb\/2023.69.9.15","journal-title":"Cell and Mol Biol"},{"key":"10458_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-024-09884-z","author":"SY Lee","year":"2024","unstructured":"Lee SY, Wu ST, Du CX, Ku HC (2024) Potential role of dipeptidyl peptidase-4 in regulating mitochondria and oxidative stress in cardiomyocytes. Cardiovasc Toxicol. https:\/\/doi.org\/10.1007\/s12012-024-09884-z","journal-title":"Cardiovasc Toxicol"},{"key":"10458_CR48","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2478\/sjecr-2019-0037","volume":"20","author":"S Bolevich","year":"2019","unstructured":"Bolevich S, Draginic N, Andjic M, Jeremic N, Bolevich S, Litvitskiy PF, Jakovljevic V, Bolevich S, Dragini N, An\u0111i\u0107 M, Jeremi\u0107 N, Bolevich S, Litvitskiy PF (2019) The effects of dpp4 inhibitors on lipid status and blood pressure in rats with diabetes mellitus type 2. Serbian J of Exp and Clin Res 20:301\u2013307. https:\/\/doi.org\/10.2478\/sjecr-2019-0037","journal-title":"Serbian J of Exp and Clin Res"},{"key":"10458_CR49","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.47009\/jamp.2024.6.1.258","volume":"6","author":"S Kumar","year":"2024","unstructured":"Kumar S, Rajak KC, Jha AK (2024) Comparative study of effect of dpp-4 inhibitors and sglt-2 inhibitors on lipid profile in patients with type 2 diabetes mellitus 2. Int J Acad Med Pharm 6:1300\u20131304. https:\/\/doi.org\/10.47009\/jamp.2024.6.1.258","journal-title":"Int J Acad Med Pharm"},{"issue":"12","key":"10458_CR50","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.26355\/eurrev_202306_32816","volume":"27","author":"AS Jarab","year":"2023","unstructured":"Jarab AS, Al-Qerem W, Alqudah S, Abu Heshmeh SR, Mukattash TL, Beiram R, Aburuz S (2023) Blood pressure control and its associated factors in patients with hypertension and type 2 diabetes. Eur Rev for Med and Pharmacol Sci 27(12):5775\u20135783. https:\/\/doi.org\/10.26355\/eurrev_202306_32816","journal-title":"Eur Rev for Med and Pharmacol Sci"},{"key":"10458_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.798958","volume":"8","author":"G Gallo","year":"2022","unstructured":"Gallo G, Volpe M, Savoia C (2022) Endothelial dysfunction in hypertension: current concepts and clinical implications. Front Med 8:1\u20138. https:\/\/doi.org\/10.3389\/fmed.2021.798958","journal-title":"Front Med"},{"issue":"4","key":"10458_CR52","doi-asserted-by":"publisher","first-page":"C972","DOI":"10.1152\/ajpcell.00246.2023","volume":"325","author":"JC Ribeiro-Silva","year":"2023","unstructured":"Ribeiro-Silva JC, Marques VB, Dos Santos L (2023) Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone. Am J Physiol Cell Physiol 325(4):C972\u2013C980. https:\/\/doi.org\/10.1152\/ajpcell.00246.2023","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10458_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/HYPERTENSIONAHA.119.13778","volume":"75","author":"P Gao","year":"2020","unstructured":"Gao P, Li L, Wei X, Wang M, Hong Y, Wu H, Shen Y, Ma T, Wei X, Zhang Q, Fang X, Wang L, Yan Z, Du GH, Zheng H, Yang G, Liu D, Zhu Z (2020) Activation of transient receptor potential channel vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) inhibitor vildagliptin protects against diabetic endothelial dysfunction. Hypertension 75(1):150\u2013162. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13778","journal-title":"Hypertension"},{"issue":"6","key":"10458_CR54","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1536\/ihj.19-117","volume":"60","author":"K Aini","year":"2019","unstructured":"Aini K, Fukuda D, Tanaka K, Higashikuni Y, Hirata Y, Yagi S, Kusunose K, Yamada H, Soeki T, Sata M (2019) Vildagliptin, a DPP-4 inhibitor, attenuates endothelial dysfunction and atherogenesis in nondiabetic apolipoprotein e-deficient mice. Int Heart J 60(6):1421\u20131429. https:\/\/doi.org\/10.1536\/ihj.19-117","journal-title":"Int Heart J"},{"key":"10458_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106855","author":"S Mi\u0161\u00fath","year":"2021","unstructured":"Mi\u0161\u00fath S, Uhrinov\u00e1 M, Klimas J, Vavrincov\u00e1-Yaghi D, Vavrinec P (2021) Vildagliptin improves vascular smooth muscle relaxation and decreases cellular senescence in the aorta of doxorubicin-treated rats. Vasc Pharmacol. https:\/\/doi.org\/10.1016\/j.vph.2021.106855","journal-title":"Vasc Pharmacol"},{"key":"10458_CR56","doi-asserted-by":"publisher","first-page":"113951","DOI":"10.1016\/j.bcp.2020.113951","volume":"177","author":"Z Chen","year":"2020","unstructured":"Chen Z, Yu J, Fu M, Dong R, Yang Y, Luo J, Hu S, Li W, Xu X, Tu L (2020) Dipeptidyl peptidase-4 inhibition improves endothelial senescence by activating AMPK\/SIRT1\/Nrf2 signaling pathway. Biochem Pharmacol 177:113951. https:\/\/doi.org\/10.1016\/j.bcp.2020.113951","journal-title":"Biochem Pharmacol"},{"key":"10458_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07436-1","author":"Y Zong","year":"2023","unstructured":"Zong Y, Wang X, Zhang Y et al (2023) Sitagliptin ameliorates Creb5\/lncRNA ENSMUST00000213271-mediated vascular endothelial dysfunction in obese mice. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-023-07436-1","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"10458_CR58","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s12276-020-00512-8","volume":"52","author":"S Seo","year":"2020","unstructured":"Seo S, Kim MK, Kim RI, Yeo Y, Kim KL, Suh W (2020) Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation. Exp Mol Med 52(10):1744\u20131753. https:\/\/doi.org\/10.1038\/s12276-020-00512-8","journal-title":"Exp Mol Med"},{"issue":"1","key":"10458_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/fcp.12831","volume":"37","author":"R Heo","year":"2023","unstructured":"Heo R, Kang M, Mun SY, Park M, Han ET, Han JH, Chun W, Park H, Jung WK, Choi IW, Park WS (2023) Antidiabetic omarigliptin dilates rabbit aorta by activating voltage-dependent K+ channels and the sarco\/endoplasmic reticulum Ca2+ -ATPase pump. Fundam Clin Pharmacol 37(1):75\u201384. https:\/\/doi.org\/10.1111\/fcp.12831","journal-title":"Fundam Clin Pharmacol"},{"key":"10458_CR60","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2147\/DMSO.S403125","volume":"16","author":"N Akashi","year":"2023","unstructured":"Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H (2023) Teneligliptin, a DPP-4 inhibitor, improves vascular endothelial function via divergent actions including changes in circulating endothelial progenitor cells. Diabetes, Metabolic Syndrome and Obesity 16:1043\u20131054. https:\/\/doi.org\/10.2147\/DMSO.S403125","journal-title":"Diabetes, Metabolic Syndrome and Obesity"},{"issue":"4","key":"10458_CR61","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/HYPERTENSIONAHA.121.18348","volume":"79","author":"JR Wilson","year":"2022","unstructured":"Wilson JR, Garner EM, Mashayekhi M, Hubers SA, Ramirez Bustamante CE, Kerman SJ, Nian H, Shibao CA, Brown NJ (2022) DPP4 (Dipeptidyl Peptidase-4) inhibition increases catecholamines without increasing blood pressure during sustained ACE (Angiotensin-Converting Enzyme) inhibitor treatment. Hypertension 79(4):827\u2013835. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18348","journal-title":"Hypertension"},{"issue":"1","key":"10458_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-019-0466-2","volume":"11","author":"A Schiapaccassa","year":"2019","unstructured":"Schiapaccassa A, Maranh\u00e3o PA, De Souza MDGC, Panazzolo DG, Nogueira Neto JF, Bouskela E, Kraemer-Aguiar LG (2019) 30-days effects of vildagliptin on vascular function, plasma viscosity, inflammation, oxidative stress, and intestinal peptides on drug-na\u00efve women with diabetes and obesity: a randomized head-to-head metformin-controlled study. Diabetol Metab Syndr 11(1):1\u20139. https:\/\/doi.org\/10.1186\/s13098-019-0466-2","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10458_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01046-z","volume":"19","author":"HB Awal","year":"2020","unstructured":"Awal HB, Nandula SR, Domingues CC, Dore FJ, Kundu N, Brichacek B, Fakhri M, Elzarki A, Ahmadi N, Safai S, Fosso M, Amdur RL, Sen S (2020) Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and\/or insulin: a randomized controlled trial. Cardiovasc Diabetol 19(1):1\u201315. https:\/\/doi.org\/10.1186\/s12933-020-01046-z","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10458_CR64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1074248418817345","volume":"24","author":"AR El-Naggar","year":"2019","unstructured":"El-Naggar AR, Zaafar D, Elyamany M, Hassanin S, Bassyouni A, Abdel-Latif H (2019) The role of vildagliptin in treating hypertension through modulating serum VEGF in diabetic hypertensive patients. J Cardiovasc Pharmacol Ther 24(3):254\u2013261. https:\/\/doi.org\/10.1177\/1074248418817345","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10458_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.599355","volume":"11","author":"X Pan","year":"2020","unstructured":"Pan X, Xu S, Li J, Tong N (2020) The effects of DPP-4 inhibitors, GLP-1RAs, and SGLT-2\/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history: insights from CVOTs and drug mechanism. Front Endocrinol 11:1\u201312. https:\/\/doi.org\/10.3389\/fendo.2020.599355","journal-title":"Front Endocrinol"},{"issue":"4","key":"10458_CR66","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bph.15462","volume":"179","author":"J Helmst\u00e4dter","year":"2022","unstructured":"Helmst\u00e4dter J, Keppeler K, K\u00fcster L, M\u00fcnzel T, Daiber A, Steven S (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014The role of the GLP-1 receptor. Br J Pharmacol 179(4):659\u2013676. https:\/\/doi.org\/10.1111\/bph.15462","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10458_CR67","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.119.14400","volume":"75","author":"K Okabe","year":"2020","unstructured":"Okabe K, Matsushima S, Ikeda S, Ikeda M, Ishikita A, Tadokoro T, Enzan N, Yamamoto T, Sada M, Deguchi H, Shinohara K, Ide T, Tsutsui H (2020) DPP (Dipeptidyl peptidase)-4 inhibitor attenuates Ang II (Angiotensin II)-induced cardiac hypertrophy via GLP (glucagon-like peptide)-1-dependent suppression of Nox (nicotinamide adenine dinucleotide phosphate oxidase) 4-HDAC (histone deacetylase) 4 pathw. Hypertension 75(4):991\u20131001. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14400","journal-title":"Hypertension"},{"issue":"2","key":"10458_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17512433.2019.1567328","volume":"12","author":"AM Patti","year":"2019","unstructured":"Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol 12(2):129\u2013143. https:\/\/doi.org\/10.1080\/17512433.2019.1567328","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10458_CR69","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jacasi.2022.09.015","volume":"3","author":"N Enzan","year":"2023","unstructured":"Enzan N, Matsushima S, Kaku H, Tohyama T, Nagata T, Ide T, Tsutsui H (2023) Beneficial effects of dipeptidyl peptidase-4 inhibitors on heart failure with preserved ejection fraction and diabetes. JACC: Asia 3:93\u2013104. https:\/\/doi.org\/10.1016\/j.jacasi.2022.09.015","journal-title":"JACC: Asia"},{"issue":"2","key":"10458_CR70","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cvr\/cvu034","volume":"102","author":"A Haghikia","year":"2014","unstructured":"Haghikia A, Ricke-Hoch M, Stapel B, Gorst I, Hilfiker-Kleiner D (2014) STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovasc Res 102(2):281\u2013289. https:\/\/doi.org\/10.1093\/cvr\/cvu034","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10458_CR71","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ejhf.633","volume":"19","author":"DH Fitchett","year":"2017","unstructured":"Fitchett DH, Udell JA, Inzucchi SE (2017) Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19(1):43\u201353. https:\/\/doi.org\/10.1002\/ejhf.633","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10458_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox10020246","volume":"10","author":"D Kawanami","year":"2021","unstructured":"Kawanami D, Takashi Y, Takahashi H, Motonaga R, Tanabe M (2021) Renoprotective effects of dpp-4 inhibitors. Antioxidants 10(2):1\u201317. https:\/\/doi.org\/10.3390\/antiox10020246","journal-title":"Antioxidants"},{"issue":"7","key":"10458_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10071573","volume":"10","author":"I V\u00f6r\u00f6s","year":"2022","unstructured":"V\u00f6r\u00f6s I, On\u00f3di Z, T\u00f3th V\u00c9, Gergely TG, S\u00e1ghy \u00c9, G\u00f6rbe A, Kem\u00e9ny \u00c1, Leszek P, Helyes Z, Ferdinandy P, Varga ZV (2022) Saxagliptin cardiotoxicity in chronic heart failure: the role of DPP4 in the regulation of neuropeptide tone. Biomedicines 10(7):1\u201317. https:\/\/doi.org\/10.3390\/biomedicines10071573","journal-title":"Biomedicines"},{"issue":"16","key":"10458_CR74","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/ijms21165756","volume":"21","author":"SN Batchu","year":"2020","unstructured":"Batchu SN, Yerra VG, Liu Y, Advani SL, Klein T, Advani A (2020) The dipeptidyl peptidase-4 inhibitor linagliptin directly enhances the contractile recovery of mouse hearts at a concentration equivalent to that achieved with standard dosing in humans. Int J Mol Sci 21(16):5756. https:\/\/doi.org\/10.3390\/ijms21165756","journal-title":"Int J Mol Sci"},{"key":"10458_CR75","doi-asserted-by":"publisher","first-page":"121648","DOI":"10.1016\/j.lfs.2023.121648","volume":"323","author":"MT Fontes","year":"2023","unstructured":"Fontes MT, Arruda-Junior DF, Dos Santos DS, Ribeiro-Silva JC, Ant\u00f4nio EL, Tucci PFJ, Rossoni LV, Girardi ACC (2023) Dipeptidyl peptidase 4 inhibition rescues PKA-eNOS signaling and suppresses aortic hypercontractility in male rats with heart failure. Life Sci 323:121648. https:\/\/doi.org\/10.1016\/j.lfs.2023.121648","journal-title":"Life Sci"},{"issue":"4","key":"10458_CR76","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","volume":"55","author":"TK Pham","year":"2023","unstructured":"Pham TK, Nguyen THT, Yi JM, Kim GS, Yun HR, Kim HK, Won JC (2023) Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice. Exp Mol Med 55(4):767\u2013778. https:\/\/doi.org\/10.1038\/s12276-023-00958-6","journal-title":"Exp Mol Med"},{"issue":"8","key":"10458_CR77","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.3390\/ijms20081940","volume":"20","author":"JI Beraldo","year":"2019","unstructured":"Beraldo JI, Benetti A, Borges-J\u00fanior FA, Arruda-Junior DF, Martins FL, Jensen L, Dariolli R, Shimizu MH, Seguro AC, Luchi WM, Girardi ACC (2019) Cardioprotection conferred by sitagliptin is associated with reduced cardiac angiotensin II\/angiotensin-(1\u20137) balance in experimental chronic kidney disease. Int J Mol Sci 20(8):1940. https:\/\/doi.org\/10.3390\/ijms20081940","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10458_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-019-0743-0","volume":"114","author":"Y Birnbaum","year":"2019","unstructured":"Birnbaum Y, Tran D, Bajaj M, Ye Y (2019) DPP - 4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3 \/ ASC inflammasome. Basic Res Cardiol 114(5):1\u201322. https:\/\/doi.org\/10.1007\/s00395-019-0743-0","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"10458_CR79","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jcmm.16122","volume":"25","author":"I Cuijpers","year":"2021","unstructured":"Cuijpers I, Papageorgiou AP, Carai P, Herwig M, M\u00fcgge A, Klein T, Hamdani N, Jones EAV, Heymans S (2021) Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. J Cell Mol Med 25(2):729\u2013741. https:\/\/doi.org\/10.1111\/jcmm.16122","journal-title":"J Cell Mol Med"},{"issue":"12","key":"10458_CR80","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, Von Eynatten M, McGuire DK, Marx N (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial. JAMA - J Am Med Assoc 322(12):1155\u20131166. https:\/\/doi.org\/10.1001\/jama.2019.13772","journal-title":"JAMA - J Am Med Assoc"},{"issue":"1","key":"10458_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0593-8","volume":"16","author":"I Gantz","year":"2017","unstructured":"Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O\u2019Neill EA, Engel SS, Kaufman KD, Lai E (2017) A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 16(1):1\u201312. https:\/\/doi.org\/10.1186\/s12933-017-0593-8","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10458_CR82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/2047487320939217","volume":"28","author":"G Cioffi","year":"2021","unstructured":"Cioffi G, Giorda CB, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP (2021) Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. Eur J of Preventive Cardiol 28(1):8\u201317. https:\/\/doi.org\/10.1177\/2047487320939217","journal-title":"Eur J of Preventive Cardiol"},{"key":"10458_CR83","doi-asserted-by":"publisher","unstructured":"Tuersun, Adili and Hou, Guanxin and Cheng, Gang, Cardiovascular events and heart failure in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an update systematic review and meta-analysis. Available at SSRN: https:\/\/ssrn.com\/abstract=4657441 or https:\/\/doi.org\/10.2139\/ssrn.4657441","DOI":"10.2139\/ssrn.4657441"},{"issue":"11","key":"10458_CR84","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/1753-0407.13449","volume":"15","author":"Y Choi","year":"2023","unstructured":"Choi Y, Ko SH, Chang K, Yoo KD, Ihm SH (2023) Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus. J Diabetes 15(11):944\u2013954. https:\/\/doi.org\/10.1111\/1753-0407.13449","journal-title":"J Diabetes"},{"issue":"6","key":"10458_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms23063346","volume":"23","author":"S Jebari-Benslaiman","year":"2022","unstructured":"Jebari-Benslaiman S, Galicia-Garc\u00eda U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Mart\u00edn C (2022) Pathophysiology of atherosclerosis. Int J Mol Sci 23(6):1\u201338. https:\/\/doi.org\/10.3390\/ijms23063346","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10458_CR86","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/jdi.14100","volume":"15","author":"IW Yen","year":"2024","unstructured":"Yen IW, Li HY (2024) Dipeptidyl peptidase-4 inhibition targeting vascular senescence as a novel treatment for atherosclerosis. J of Diabetes Investigation 15(2):143\u2013144. https:\/\/doi.org\/10.1111\/jdi.14100","journal-title":"J of Diabetes Investigation"},{"issue":"10","key":"10458_CR87","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.cell.2022.04.004","volume":"185","author":"JLM Bj\u00f6rkegren","year":"2022","unstructured":"Bj\u00f6rkegren JLM, Lusis AJ (2022) Atherosclerosis: recent developments. Cell 185(10):1630\u20131645. https:\/\/doi.org\/10.1016\/j.cell.2022.04.004","journal-title":"Cell"},{"issue":"9","key":"10458_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22094633","volume":"22","author":"RV Giglio","year":"2021","unstructured":"Giglio RV, Stoian AP, Al-Rasadi K, Banach M, Patti AM, Ciaccio M, Rizvi AA, Rizzo M (2021) Novel therapeutical approaches to managing atherosclerotic risk. Int J Mol Sci 22(9):1\u201318. https:\/\/doi.org\/10.3390\/ijms22094633","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10458_CR89","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2169\/internalmedicine.2616-19","volume":"58","author":"T Morishita","year":"2019","unstructured":"Morishita T, Uzui H, Ikeda H, Amaya N, Kaseno K, Ishida K, Fukuoka Y, Tada H (2019) Effects of sitagliptin on the coronary flow reserve, circulating endothelial progenitor cells and stromal cell-derived factor-1alpha. Intern Med 58(19):2773\u20132781. https:\/\/doi.org\/10.2169\/internalmedicine.2616-19","journal-title":"Intern Med"},{"issue":"6","key":"10458_CR90","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.3390\/ijms23063065","volume":"23","author":"SC Wang","year":"2022","unstructured":"Wang SC, Wang XY, Liu CT, Chou RH, Chen ZB, Huang PH, Lin SJ (2022) The Dipeptidyl peptidase-4 inhibitor linagliptin ameliorates endothelial inflammation and microvascular thrombosis in a sepsis mouse model. Int J of Mol Sci 23(6):3065. https:\/\/doi.org\/10.3390\/ijms23063065","journal-title":"Int J of Mol Sci"},{"key":"10458_CR91","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165933","author":"AB Herman","year":"2023","unstructured":"Herman AB, Tsitsipatis D, Anerillas C, Mazan-Mamczarz K, Carr AE, Gregg JM, Wang M, Zhang J, Michel M, Henry-Smith CA, Harris SC, Munk R, Martindale JL, Piao Y, Fan J, Mattison JA, De S, Abdelmohsen K, Maul RW, Gorospe M (2023) DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice. J of Clin Investigation. https:\/\/doi.org\/10.1172\/JCI165933","journal-title":"J of Clin Investigation"},{"issue":"1","key":"10458_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00380-020-01689-8","volume":"36","author":"T Kurosawa","year":"2021","unstructured":"Kurosawa T, Li Y, Sudo M, Haruta H, Hagikura K, Takayama T, Hiro T, Shiomi M, Hao H, Matsumoto T, Hirayama A, Okumura Y (2021) Effect of the dipeptidyl peptidase-4 inhibitor linagliptin on atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits: iMap-IVUS and pathological analysis. Heart Vessels 36(1):127\u2013135. https:\/\/doi.org\/10.1007\/s00380-020-01689-8","journal-title":"Heart Vessels"},{"issue":"11","key":"10458_CR93","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00210-019-01660-z","volume":"392","author":"L Pirzeh","year":"2019","unstructured":"Pirzeh L, Babapour V, Badalzadeh R, Panahi N (2019) Pretreatment with vildagliptin boosts ischemic-postconditioning effects on cardioprotection and expression profile of genes regulating autophagy and mitochondrial fission\/fusion in diabetic heart with reperfusion injury. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 392(11):1371\u20131382. https:\/\/doi.org\/10.1007\/s00210-019-01660-z","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"4","key":"10458_CR94","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1440-1681.13450","volume":"48","author":"J Bradic","year":"2021","unstructured":"Bradic J, Milosavljevic I, Bolevich S, Litvitskiy PF, Jeremic N, Bolevich S, Zivkovic V, Srejovic I, Jeremic J, Jovicic N, Mitrovic S, Jakovljevic V (2021) Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia\u2013reperfusion injury in rats with diabetes mellitus type 2. Clin Exp Pharmacol Physiol 48(4):575\u2013584. https:\/\/doi.org\/10.1111\/1440-1681.13450","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10458_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2022.09.005","volume":"360","author":"K Okada","year":"2022","unstructured":"Okada K, Kikuchi S, Kuji S, Nakayama N, Maejima N, Matsuzawa Y, Iwahashi N, Kosuge M, Ebina T, Kimura K, Tamura K, Hibi K (2022) Impact of early intervention with alogliptin on coronary plaque regression and stabilization in patients with acute coronary syndromes. Atherosclerosis 360:1\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.09.005","journal-title":"Atherosclerosis"},{"key":"10458_CR96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2020.03.015","volume":"300","author":"B Li","year":"2020","unstructured":"Li B, Luo YR, Tian F, Chen YD, Tian JW, Ding Y, Zhu M, Li JW, Zhang YQ, Shi WM (2020) Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. Atherosclerosis 300:10\u201318. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10458_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01061-0","volume":"19","author":"M Furuhashi","year":"2020","unstructured":"Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, Sakuma M, Shimabukuro M, Nomiyama T, Arasaki O, Node K, Ueda S (2020) Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovasc Diabetol 19(1):1\u201310. https:\/\/doi.org\/10.1186\/s12933-020-01061-0","journal-title":"Cardiovasc Diabetol"},{"issue":"19","key":"10458_CR98","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.3390\/jcm11195776","volume":"11","author":"PRR Genestreti","year":"2022","unstructured":"Genestreti PRR, Furtado RHM, Salsoso R, Dal\u00e7\u00f3quio TF, Franci A, Menezes FR, Caporrino C, Ferrari AG, Nakashima CAK, Scanavini Filho MA, Lima FG, Giraldez RRCV, Baracioli LM, Nicolau JC (2022) Effects of DPP4 inhibitor in platelet reactivity and other cardiac risk markers in patients with type 2 diabetes and acute myocardial infarction. J of Clin Med 11(19):5776. https:\/\/doi.org\/10.3390\/jcm11195776","journal-title":"J of Clin Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10458-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:32:42Z","timestamp":1766853162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10458-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10458"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10458-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors disclosed no potential conflicts of interest concerning the research, authorship, and publication of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"400"}}